Sector Report · Recent · Healthcare briefing

Pharmaceutical Companies Increase Investment in Rare Disease Treatment Development

Pharmaceutical and biotech companies are increasingly allocating capital toward the development of orphan drugs for rare diseases.

What it means for you ↓ Courses for this story

31%salary uplift reported after healthcare management certification

13%projected growth in health services roles this decade

2.1xmore interview callbacks with a verified credential

20days to your first credential

The briefing

The story
in brief.

What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.

Pharmaceutical and biotech companies are increasingly allocating capital toward the development of orphan drugs for rare diseases. This strategic shift is driven by favourable regulatory incentives that accelerate approval processes and ensure market exclusivity. Consequently, there is a growing demand for scientists specialising in genomics and rare disease pathways. This trend creates distinct career opportunities within specialised research laboratories, signalling a structural change in where innovation capital is deployed within the wider healthcare sector.

Employer demand for AI in Pharmaceuticals skills — indexed growth since 2019
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)

Your move

What this means
for your career.

Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.

This shift elevates the value of specialised scientific expertise, particularly in genomics and molecular biology. If you work in life sciences, you should pay close attention to niche therapeutic areas rather than broad-spectrum drug development. Upskilling in regulatory affairs for orphan drugs will also distinguish you in a competitive job market. A smart professional would immediately update their CV to highlight any experience with rare disease pathways or genetic analysis. Consider enrolling in targeted courses on regulatory compliance or advanced genomics to align your skill set with this emerging demand. Proactively networking with firms specialising in orphan drugs can also uncover hidden opportunities in this rapidly evolving sector.

For this story, the fields that convert it into pay are AI in Pharmaceuticals, Healthcare, Compliance And Governance and Data Science — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.

Indicative salary uplift in the fields matched to this story
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below

Matched to this story

Enrol in these
to benefit.

These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.